{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:35:36Z","timestamp":1793216136712,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacadv.2026.103233","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:56:44Z","timestamp":1789171004000},"page":"103233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["PCSK9 Inhibitors and Risk of Aortic Stenosis in Atherosclerotic Cardiovascular Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Jheng-Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Wei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1723-828X","authenticated-orcid":false,"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jacadv.2026.103233_bib1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11427-025-2948-y","article-title":"Global burden of atherosclerotic cardiovascular disease attributed to lifestyle and metabolic risks","volume":"68","author":"Xu","year":"2025","journal-title":"Sci China Life Sci"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103233_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12889-023-17619-y","article-title":"Epidemiology of multimorbidity associated with atherosclerotic cardiovascular disease in the United States, 1999-2018","volume":"24","author":"Tian","year":"2024","journal-title":"BMC Public Health"},{"issue":"39","key":"10.1016\/j.jacadv.2026.103233_bib3","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103233_bib4","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jacc.2017.01.025","article-title":"Association between cardiovascular risk factors and aortic stenosis: the CANHEART aortic stenosis study","volume":"69","author":"Yan","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacadv.2026.103233_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.acvd.2023.07.008","article-title":"Independent association of aortic stenosis with many known cardiovascular risk factors and many inflammatory diseases","volume":"116","author":"Movahed","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103233_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.jacadv.2026.103233_bib7","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103233_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2013.49.1.1","article-title":"Role of statins in coronary artery disease","volume":"49","author":"Lim","year":"2013","journal-title":"Chonnam Med J"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103233_bib9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/cvr\/cvaf159","article-title":"Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification","volume":"121","author":"Jiang","year":"2025","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103233_bib10","article-title":"Impact of lipoprotein(a) on valvular and cardiovascular outcomes in patients with Calcific aortic valve stenosis","volume":"14","author":"Girard","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103233_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacbts.2020.05.004","article-title":"Genetic and in vitro inhibition of PCSK9 and calcific aortic valve stenosis","volume":"5","author":"Perrot","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jacadv.2026.103233_bib12","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"10.1016\/j.jacadv.2026.103233_bib13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/CLEP.S265619","article-title":"Validity of acute cardiovascular outcome diagnoses recorded in European electronic health records: a systematic review","volume":"12","author":"Davidson","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103233_bib14","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.25011\/cim.v44i2.36354","article-title":"Validation of diagnosis and procedure codes for revascularization for peripheral artery disease in Ontario administrative databases","volume":"44","author":"Jacob-Brassard","year":"2021","journal-title":"Clin Invest Med"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103233_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103233_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaf014","article-title":"Prognostic benefit of GLP-1 RA addition to SGLT2i in patients with ASCVD and heart failure: a cohort study","volume":"11","author":"Chen","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103233_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ehjcvp\/pvae093","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis","volume":"11","author":"Lin","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacadv.2026.103233_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ahj.2017.09.004","article-title":"Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR Research to Practice (R2P) project","volume":"195","author":"Hess","year":"2018","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.jacadv.2026.103233_bib19","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103233_bib20","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1038\/s41467-025-59616-2","article-title":"Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study","volume":"16","author":"Lin","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103233_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.jacadv.2026.103233_bib22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103233_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103233_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/ehjcvp\/pvae092","article-title":"Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study","volume":"11","author":"Ciofani","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"40","key":"10.1016\/j.jacadv.2026.103233_bib25","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1093\/eurheartj\/ehaa070","article-title":"Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study","volume":"41","author":"Nazarzadeh","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103233_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1186\/s12872-024-04321-z","article-title":"Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103233_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103233_bib28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103233_bib29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103233_bib30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103233_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40119-024-00353-w","article-title":"Targeting lipoprotein(a): can RNA therapeutics provide the next step in the prevention of cardiovascular disease?","volume":"13","author":"Thau","year":"2024","journal-title":"Cardiol Ther"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103233_bib32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1194\/jlr.R051870","article-title":"Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis","volume":"57","author":"Thanassoulis","year":"2016","journal-title":"J Lipid Res"},{"issue":"20","key":"10.1016\/j.jacadv.2026.103233_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103233_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s40364-024-00712-8","article-title":"PCSK9 in T-cell function and the immune response","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103233_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/0929867328666210707192625","article-title":"PCSK 9: a link between inflammation and atherosclerosis","volume":"29","author":"Patriki","year":"2022","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103233_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006339","article-title":"Valve interstitial cells: the key to understanding the pathophysiology of heart valve calcification","volume":"6","author":"Rutkovskiy","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103233_bib37","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jacc.2013.05.015","article-title":"Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study","volume":"62","author":"Osnabrugge","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103233_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5090\/jcs.24.048","article-title":"Costs associated with transcatheter aortic valve implantation and surgical aortic valve replacement in Korea","volume":"57","author":"Sohn","year":"2024","journal-title":"J Chest Surg"},{"issue":"19","key":"10.1016\/j.jacadv.2026.103233_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.042112","article-title":"Rationale and design of the EPISODE trial: a randomized controlled trial on the effect of PCSK9 inhibitors in calcific aortic valve stenosis","volume":"14","author":"Zheng","year":"2025","journal-title":"J Am Heart Assoc"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2600654X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2600654X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:25:22Z","timestamp":1793215522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X2600654X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2772963X2600654X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103233","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 Inhibitors and Risk of Aortic Stenosis in Atherosclerotic Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103233"}}